2-Apr-2026
PRNewswire (Wed, 1-Apr 9:00 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Wed, 1-Apr 8:21 AM ET)
Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and Agios Pharma (AGIO)
TipRanks (Wed, 1-Apr 6:20 AM ET)
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?
Benzinga (Tue, 31-Mar 12:39 PM ET)
TipRanks (Tue, 31-Mar 10:45 AM ET)
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion
Seeking Alpha News (Tue, 31-Mar 9:07 AM ET)
PRNewswire (Tue, 31-Mar 9:00 AM ET)
Market Chameleon (Tue, 31-Mar 4:13 AM ET)
Globe Newswire (Tue, 31-Mar 7:00 AM ET)
PRNewswire (Wed, 25-Mar 9:01 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of April 2, 2026, AGIO stock price climbed to $35.20 with 1,251,258 million shares trading.
AGIO has a beta of 1.87, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.20 to the broad based SPY ETF.
AGIO has a market cap of $2.06 billion. This is considered a Mid Cap stock.
Last quarter Agios Pharmaceuticals reported $20 million in Revenue and -$1.86 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.10.
In the last 3 years, AGIO traded as high as $62.58 and as low as $19.80.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): XBI, VTI, IWM, VB, VBK.
AGIO has outperformed the market in the last year with a price return of +28.5% while the SPY ETF gained +18.2%. AGIO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +29.3% and +25.1%, respectively, while the SPY returned -3.6% and -0.6%, respectively.
AGIO support price is $33.17 and resistance is $35.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.